Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: HS627|DRUG: Pertuzumab
Sponsor: BioRay Pharmaceutical Co., Ltd.